Natera Updates On Patent Ruling In Litigation With NeoGenomics

Natera (NTRA) reported that a U.S. District Court invalidated certain claims in two patents it asserted against NeoGenomics' RaDaR v1.1 test, marking a partial legal setback. However, the company emphasized that the ruling does not impact its critical U.S. Patent No. 11,519,035, which previously supported injunctions against NeoGenomics' RaDaR v1.0. Natera is currently reviewing its options, including potential appeals or further enforcement actions, while reaffirming its commitment to defending its extensive intellectual property portfolio and investments in innovation.

Analysis

Natera, Inc. (NTRA) has experienced a mixed outcome in its ongoing patent litigation with NeoGenomics (NEO). A U.S. District Court invalidated certain claims in two of Natera's patents that were asserted against NeoGenomics' RaDaR v1.1 test, representing a tactical setback for Natera and a partial victory for NeoGenomics. However, the material insight for investors is that this ruling does not affect Natera's key U.S. Patent No. 11,519,035. This specific patent remains valid and was previously instrumental in securing injunctions that removed NeoGenomics' earlier RaDaR v1.0 product from the market, indicating Natera's core intellectual property moat for that technology is so far intact. The market's muted reaction, with NTRA's stock trading up a marginal 0.19%, aligns with the low market impact score and suggests investors are weighing the preservation of the more critical '035 patent more heavily than the loss of the other claims. Natera's statement reaffirming its intent to defend its portfolio of over 500 patents, potentially through an appeal or other enforcement actions, signals that litigation will remain a key strategic tool and a persistent factor in the competitive landscape.

Key Decisions for Investors

• Investors in Natera should monitor the ongoing litigation with NeoGenomics, as the invalidation of these secondary patents, while not critical, demonstrates that its broad IP portfolio is not immune to legal challenges.
• The preservation of U.S. Patent No. 11,519,035 is a significant positive, suggesting Natera's primary competitive barrier remains secure for now, which may reinforce a hold thesis for current investors.
• For those monitoring NeoGenomics, this court ruling is a favorable development that de-risks its RaDaR v1.1 product to an extent, though the overhang from Natera's broader and still-enforceable patent portfolio persists.
• Given the high-stakes nature of intellectual property in the precision medicine sector, portfolio allocation should consider a company's entire litigation strategy and patent depth, not just the outcome of a single ruling.